Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Prime Medicine (PRME) Gains from Investment Securities: 2020-2024

Historic Gains from Investment Securities for Prime Medicine (PRME) over the last 5 years, with Dec 2024 value amounting to $44.9 million.

  • Prime Medicine's Gains from Investment Securities rose 86.40% to $83.8 million in Q1 2025 from the same period last year, while for Mar 2025 it was $132.0 million, marking a year-over-year increase of 173.67%. This contributed to the annual value of $44.9 million for FY2024, which is 1276.26% up from last year.
  • Latest data reveals that Prime Medicine reported Gains from Investment Securities of $44.9 million as of FY2024, which was up 1,276.26% from $3.3 million recorded in FY2023.
  • Prime Medicine's Gains from Investment Securities' 5-year high stood at $44.9 million during FY2024, with a 5-year trough of $126,000 in FY2020.
  • In the last 3 years, Prime Medicine's Gains from Investment Securities had a median value of $28.6 million in 2022 and averaged $25.6 million.
  • Per our database at Business Quant, Prime Medicine's Gains from Investment Securities spiked by 9,633.33% in 2021 and then crashed by 88.58% in 2023.
  • Over the past 5 years, Prime Medicine's Gains from Investment Securities (Yearly) stood at $126,000 in 2020, then soared by 9,633.33% to $12.3 million in 2021, then spiked by 133.12% to $28.6 million in 2022, then tumbled by 88.58% to $3.3 million in 2023, then spiked by 1,276.26% to $44.9 million in 2024.